^
    Back
    Association details:
    Biomarker:EGFR L858R
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Sci Rep
    Title:

    The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

    Published date:
    08/26/2022
    Excerpt:
    Patients with EGFR L858R mutation treated with anti-angiogenic therapy in their course of treatment had a significantly prolonged OS compared to those who had never received an anti-angiogenic agent.
    DOI:
    https://doi.org/10.1038/s41598-022-18889-z